You are here: Industry Insights > AbbVie

News List

FDA Approves AbbVie's New RA Drug contractpharma
August 20, 2019
Approximately 30 percent of patients treated with RINVOQ achieved clinical remission at week 12 and week 14.
AbbVie was Allergan's only suitor in $63B takeover that shocked the industry fiercepharma
August 15, 2019
AbbVie’s $63 billion, megatakeover agreement for Allergan took most of the industry by surprise when the two drugmakers dropped the news in late June.
AbbVie’s $63B Allergan buyout offer depends on Botox growth. But will it last? fiercepharma
August 07, 2019
An enduring medical aesthetics franchise, led by wrinkle-fighter Botox, is one of the key reasons AbbVie is shelling out $63 billion for Allergan. That drug has again pulled off a sales jump, though a slower growth rate suggests a tough game ahead.
AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib fiercepharma
July 29, 2019
AbbVie is in the early stages of its Humira biosimilar slide after European copycats rolled out last fall. But thankfully for the drugmaker, it has a psoriasis launch handily besting expectations.
AbbVie acquires STING pathway-focused Mavupharma pharmaceutical-technology
July 17, 2019
Chicago-based AbbVie has announced its acquisition of Seattle-based oncology drug discovery company Mavupharma. The financial terms of the transaction were not disclosed.
AbbVie Acquires Mavupharma americanpharmaceuticalreview
July 17, 2019
AbbVie has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer.
CytomX Therapeutics Announces Second Target Selection with AbbVie contractpharma
July 10, 2019
Multi-Program oncology collaboration triggers $10 million milestone payment to CytomX.
AbbVie is to acquire Allergan in a ‘transformative transaction’ europeanpharmaceuticalreview
June 28, 2019
AbbVie Inc. and Allergan plc have entered into a definitive transaction agreement under which AbbVie will acquire Allergan.
FDA lifts hold on AbbVie, Roche's Venclexta in myeloma after drugmakers pledge risk remedies fiercepharma
June 28, 2019
After a spate of trial deaths forced AbbVie and Roche to halt trial enrollment for oncology med Venclexta in multiple myeloma, the future seemed dim for the drug’s expansion hopes in the disease. But now, after taking steps to increase safety, the drugmak
AbbVie, nearing the end of Humira's historic run, scoops up a struggling Allergan for $63B fiercepharma
June 28, 2019
It's not the first time Allergan has brought in a pharma suitor for a takeout. Previously, the company was set to merge with Pfizer in a $160 billion tax inversion, but the companies called it off in the wake of new Treasury rules. That deal valued Allerg

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page